Similar articles for PMID: 25584281

Year	Number of Results
2003	1
2006	4
2007	5
2008	1
2009	2
2011	3
2012	3
2013	3
2014	7
2015	3
2016	3
2017	6
2018	9
2019	4
2020	2
2021	1
2022	3
2024	0

1

Diffuse hypopigmentation followed by hyperpigmentation in an african american woman with hemangiopericytoma treated with dasatinib.

Boudadi K, Chugh R. Boudadi K, et al. J Clin Diagn Res. 2014 Nov;8(11):QD01-2. doi: 10.7860/JCDR/2014/8055.5160. Epub 2014 Nov 20. J Clin Diagn Res. 2014. PMID: 25584281 Free PMC article.

2

[Variables associated with BCR-ABL kinase domain mutation in TKI-resistant patients with chronic myeloid leukemia].

Shi DY, Qin YZ, Lai YY, Shi HX, Huang XJ, Jiang Q. Shi DY, et al. Zhonghua Xue Ye Xue Za Zhi. 2020 Jun 14;41(6):469-476. doi: 10.3760/cma.j.issn.0253-2727.2020.06.006. Zhonghua Xue Ye Xue Za Zhi. 2020. PMID: 32654459 Free PMC article. Chinese.

3

Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.

Ferri C, Bianchini M, Bengió R, Larripa I. Ferri C, et al. Blood Cells Mol Dis. 2014 Feb-Mar;52(2-3):121-5. doi: 10.1016/j.bcmd.2013.09.002. Epub 2013 Oct 3. Blood Cells Mol Dis. 2014. PMID: 24091144

4

Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.

Fiskus W, Pranpat M, Balasis M, Bali P, Estrella V, Kumaraswamy S, Rao R, Rocha K, Herger B, Lee F, Richon V, Bhalla K. Fiskus W, et al. Clin Cancer Res. 2006 Oct 1;12(19):5869-78. doi: 10.1158/1078-0432.CCR-06-0980. Clin Cancer Res. 2006. PMID: 17020995

5

Development of Asymmetric Facial Depigmentation in a Patient Treated with Dasatinib with New-Onset Hypovitaminosis D: Case Report and Review of the Literature.

Webb KC, Harasimowicz M, Janeczek M, Speiser J, Swan J, Tung R. Webb KC, et al. Case Rep Dermatol Med. 2017;2017:9359086. doi: 10.1155/2017/9359086. Epub 2017 Mar 23. Case Rep Dermatol Med. 2017. PMID: 28424749 Free PMC article.

6

Imatinib-induced diffuse hyperpigmentation of the oral mucosa, the skin, and the nails in a patient affected by chronic myeloid leukemia: report of a case and review of the literature.

Di Tullio F, Mandel VD, Scotti R, Padalino C, Pellacani G. Di Tullio F, et al. Int J Dermatol. 2018 Jul;57(7):784-790. doi: 10.1111/ijd.13931. Epub 2018 Feb 8. Int J Dermatol. 2018. PMID: 29417559 Review.

7

Hair depigmentation during chemotherapy with dasatinib, a dual Bcr-Abl/Src family tyrosine kinase inhibitor.

Sun A, Akin RS, Cobos E, Smith J. Sun A, et al. J Drugs Dermatol. 2009 Apr;8(4):395-8. J Drugs Dermatol. 2009. PMID: 19363859

8

Pigmentary changes in a patient treated with imatinib.

Balagula Y, Pulitzer MP, Maki RG, Myskowski PL. Balagula Y, et al. J Drugs Dermatol. 2011 Sep;10(9):1062-6. J Drugs Dermatol. 2011. PMID: 22052279

9

Dasatinib-Induced Hypopigmentation in Pediatric Patient with Chronic Myeloid Leukemia: A Case Report and Review of the Literature.

Alharbi B, Alamri S, Mahdi A, Marghalani S. Alharbi B, et al. Case Rep Dermatol Med. 2018 Jul 9;2018:4062431. doi: 10.1155/2018/4062431. eCollection 2018. Case Rep Dermatol Med. 2018. PMID: 30112222 Free PMC article.

10

Imatinib mesylate causes hypopigmentation in the skin.

Tsao AS, Kantarjian H, Cortes J, O'Brien S, Talpaz M. Tsao AS, et al. Cancer. 2003 Dec 1;98(11):2483-7. doi: 10.1002/cncr.11812. Cancer. 2003. PMID: 14635084 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

53 results

Results by year